Delta Variant: J&J COVID-19 Vaccine Shows Promising Results
Johnson & Johnson have announced that findings from a laboratory study have shown promising results for it its single-dose COVID-19 vaccine against the Delta variant. Blood analysis drawn from eight patients revealed that immune responses to the Delta variant were...
FDA Approves HDT Bio COVID-19 Vaccine Phase 1 Clinical Trial
The FDA (Food and Drug Administration) has evaluated HDT Bio Corp’s Investigational New Drug (IND) Application and given the company the green light for a Phase 1 clinical trial of its HDT-301 COVID-19 RNA vaccine. HDT Bio, a developer of immunotherapies for oncology...
NuVasive Pulse Receives CE Mark, Begins Clinical Evaluations
With an aim to transform disruptive spine surgery, NuVasive (NASDAQ: NUVA), a leader in spine technology innovation, announced that clinical evaluations have started for its Pulse® platform which recently received CE Mark (Conformitè Europëenne) approval. The Pulse...
Yiling Pharmaceutical Gains Market Access in the Ukraine
Yiling Pharmaceutical has received medicine registration document from the Ministry of Health of Ukraine for its drug therapy Lianhua Qingwen Capsules. Lianhua Qingwen Capsules are designed to treat COVID-19, as well as other viruses like the flu or cold. The medicine...
FDA Grants Fast Track Designation to Syndax Pharmaceuticals
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Syndax Pharmaceuticals for the treatment of relapsed/refractory acute leukemia with either MLLr or NPM1 mutations called SNDX-5613. Previously, SNDX-5613 was granted Orphan Drug...
PMDA Grants Regulatory Approval for Leukemia Drug Therapy
Japan's regulatory body, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), has granted HUYABIO International, Shenzhen Chipscreen Biosciences' licensing partner, regulatory approval for leukemia drug therapy, Tucidinostat. Tucidinostat, also referred to...